DJIA 18,232.02 -53.72 -0.29%
NASDAQ 5,089.36 -1.43 -0.03%
S&P 500 2,126.06 -4.76 -0.22%
market minute promo

Exelixis (NASDAQ: EXEL)



company name or ticker

'Mad Money' Lightning Round: Buy Disney, Be Careful With Exelixis

Stifel Talks 5 Biotech Stocks

Exelixis (EXEL) Worth Watching: Stock Moves 10.3% Higher - Tale of the Tape

Exelixis (EXEL) Stock Spikes on First Quarter Earnings Report

You'll Never Guess Why Exelixis, Inc. Romped 14% Higher

Exelixis soars 14% after the company reports better-than-expected first-quarter results, but is something else in its report responsible for today's monstrous gains?

Waiting for Exelixis, Inc.'s Meteor to Land

Data from the biotech's kidney cancer trial won't be available until late in the second quarter or potentially even later.

Exelixis' (EXEL) CEO Mike Morrissey on Q1 2015 Results - Earnings Call Transcript

Will Endocyte (ECYT) Disappoint This Earnings Season? - Analyst Blog

Is Exelixis (EXEL) Likely to Report Narrower Loss in Q1? - Analyst Blog

Will Vertex (VRTX) Surprise with a Lower Loss in Q1? - Analyst Blog

See More Articles...